Is CureVac NV overvalued or undervalued?

As of 24 October 2025, the valuation grade for CureVac NV has moved from attractive to very attractive, indicating a strong improvement in its perceived value. The company is currently considered undervalued, supported by a P/E ratio of 5, an EV to EBITDA of 1.90, and a PEG ratio of 0.03, which suggests significant growth potential relative to its price.
In comparison to its peers, CureVac NV's P/E ratio is notably lower than PTC Therapeutics, Inc. at 5.85 and Harmony Biosciences Holdings, Inc. at 11.40, reinforcing its undervaluation. Additionally, while CureVac has experienced a year-to-date return of 57.18%, significantly outperforming the S&P 500's return of 15.47%, its long-term performance over the past five years shows a decline of 89.29%, highlighting volatility. Overall, these metrics suggest that CureVac NV is positioned as an attractive investment opportunity within the pharmaceuticals and biotechnology sector.